Hanmi Pharm Co Ltd Asset Resilience Ratio
Hanmi Pharm Co Ltd asset resilience ratio. Hanmi Pharm Co Ltd (128940) has an Asset Resilience Ratio of 6.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 128940 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hanmi Pharm Co Ltd (2010–2024)
Asset resilience ratio of Hanmi Pharm Co Ltd from 2010 to 2024. This chart shows how Hanmi Pharm Co Ltd's Asset Resilience Ratio has changed over time. Read Hanmi Pharm Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hanmi Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Hanmi Pharm Co Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩140.92 Billion | 6.91% |
| Total Liquid Assets | ₩140.92 Billion | 6.91% |
Asset Resilience Insights
- Limited Liquidity: Hanmi Pharm Co Ltd maintains only 6.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hanmi Pharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hanmi Pharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
China Shineway Pharmaceutical Group Limited
F:C1S |
Drug Manufacturers - Specialty & Generic | 3.49% |
|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SHG:688505 |
Drug Manufacturers - Specialty & Generic | 11.06% |
|
Chong Kun Dang Pharmaceutical
KO:185750 |
Drug Manufacturers - Specialty & Generic | 6.04% |
Hanmi Pharm Co Ltd Asset Resilience Ratio by Year (2010–2024)
Hanmi Pharm Co Ltd asset resilience ratio by year from 2010 to 2024. The table below shows the annual Asset Resilience Ratio data for Hanmi Pharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.05% | ₩917.66 Million ≈ $621.88K |
₩2.02 Trillion ≈ $1.37 Billion |
-10.50pp |
| 2023-12-31 | 10.54% | ₩200.20 Billion ≈ $135.67 Million |
₩1.90 Trillion ≈ $1.29 Billion |
+5.90pp |
| 2022-12-31 | 4.65% | ₩89.41 Billion ≈ $60.59 Million |
₩1.92 Trillion ≈ $1.30 Billion |
+4.52pp |
| 2021-12-31 | 0.13% | ₩2.51 Billion ≈ $1.70 Million |
₩1.94 Trillion ≈ $1.31 Billion |
+0.03pp |
| 2020-12-31 | 0.10% | ₩1.87 Billion ≈ $1.27 Million |
₩1.88 Trillion ≈ $1.28 Billion |
0.00pp |
| 2019-12-31 | 0.10% | ₩1.98 Billion ≈ $1.34 Million |
₩1.91 Trillion ≈ $1.30 Billion |
-1.75pp |
| 2018-12-31 | 1.85% | ₩31.36 Billion ≈ $21.25 Million |
₩1.69 Trillion ≈ $1.15 Billion |
-3.75pp |
| 2017-12-31 | 5.61% | ₩93.12 Billion ≈ $63.11 Million |
₩1.66 Trillion ≈ $1.13 Billion |
-6.91pp |
| 2016-12-31 | 12.51% | ₩199.83 Billion ≈ $135.42 Million |
₩1.60 Trillion ≈ $1.08 Billion |
+9.95pp |
| 2015-12-31 | 2.57% | ₩44.20 Billion ≈ $29.95 Million |
₩1.72 Trillion ≈ $1.17 Billion |
-1.83pp |
| 2014-12-31 | 4.40% | ₩45.42 Billion ≈ $30.78 Million |
₩1.03 Trillion ≈ $700.28 Million |
-0.19pp |
| 2013-12-31 | 4.59% | ₩40.41 Billion ≈ $27.38 Million |
₩880.87 Billion ≈ $596.95 Million |
+0.75pp |
| 2012-12-31 | 3.84% | ₩32.06 Billion ≈ $21.72 Million |
₩835.59 Billion ≈ $566.27 Million |
+2.60pp |
| 2011-12-31 | 1.24% | ₩9.76 Billion ≈ $6.61 Million |
₩787.75 Billion ≈ $533.85 Million |
+0.72pp |
| 2010-12-31 | 0.52% | ₩3.89 Billion ≈ $2.63 Million |
₩747.72 Billion ≈ $506.72 Million |
-- |
About Hanmi Pharm Co Ltd
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two activ… Read more